|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 1. Demographic data postmortem tissue** | | | | | | |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
|  | **Clinical** | **Pathological** |  |  |  |  | **Grade** | **Grade** |  |
|  | **diagnosis** | **diagnosis** | **Sex** | **Age** | **PMD (h)** | **Brain areas** | **(Braak, NFT)** | **(Braak, Aβ)** |  |
| 1 | CON | CON | M | 78 | 17.4 | Hipp/Temp | I | 0 |  |
| 2 | CON | CON | F | 75 | 5.25 | Hipp/Temp | I | O |  |
| 3 | CON | CON | F | 60 | 6.50 | Temp | I | O |  |
| 4 | CON | CON | M | 82 | 5.50 | Hipp/Temp | I | O |  |
| 5 | CON | CON | F | 85 | 7.05 | Hipp/Temp | I | B |  |
| 6 | CON | CON | F | 84 | 6.05 | Hipp/Temp | II | B |  |
| 7 | CON | CON | F | 83 | 4.40 | Hipp/Temp | II | B |  |
| 8 | CON | CON | F | 73 | 7.45 | Hipp/Temp | I | B |  |
| 9 | AD | AD | F | 84 | 4.50 | Hipp/Temp | V | C |  |
| 10 | AD | AD | M | 74 | 5.35 | Hipp | VI | C |  |
| 11 | AD | AD | F | 87 | 8 | Hipp/Temp | VI | C |  |
| 12 | AD | AD | M | 73 | 6.15 | Hipp/Temp | VI | C |  |
| 13 | AD | AD | F | 81 | 6.00 | Hipp | VI | C |  |
| 14 | AD | AD | F | 82 | 5.3 | Hipp | VI | C |  |
| 15 | AD | AD | F | 62 | 4.45 | Hipp/Temp | VI | C |  |
| 16 | AD | AD | M | 74 | 7.40 | Hipp/Temp | VI | C |  |
|  |  |  |  |  |  |  |  |  |  |

Braak stages were established as described in Materials and Methods.

CON, Control cases with no cognitive dysfunction; AD, Alzheimer’s disease; F, female; M, male; PMD, postmortem delay (h = hours); Hipp, hippocampus; Temp, temporal cortex